Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study

February 19, 2009 at 8:00 am Leave a comment


Sanofi Pasteur, the vaccines division of sanofi-aventis Group
(EURONEXT : SAN and NYSE : SNY), announced today that its investigational
tetravalent dengue vaccine is entering into a pediatric clinical study in
Thailand to assess the efficacy of the vaccine in protecting children against
dengue, the most widespread tropical disease after malaria. Sanofi Pasteur’s
tetravalent dengue vaccine candidate is the first to reach this stage of
clinical development.



Sanofi Pasteur is collaborating with Mahidol University of
Thailand, the Ministry of Public Health, and the Pediatric Dengue Vaccine
Initiative (PDVI) to conduct this efficacy study in the province of
Ratchaburi.



“Large scale pediatric studies are instrumental for the
development of a safe and efficacious dengue vaccine to protect against a
disease that primarily affects children,” said Dr. Pratap Singhasivanon, Dean
of the Faculty of Tropical Medicine, Mahidol University. “We are happy to
contribute to an important milestone with the actual start of an efficacy
study in Ratchaburi.”




The Sanofi Pasteur clinical study program follows guidelines
from the Initiative for Vaccine Research (IVR) led by the World Health
Organization (WHO), which fosters the global efforts towards dengue vaccine
development.



“WHO is committed to the availability of a dengue vaccine that
will ultimately benefit children in endemic countries,” said Dr. Joachim
Hombach, Coordinator Implementation Research for IVR, WHO.



About Sanofi Pasteur dengue vaccine global clinical study
program



Sanofi Pasteur started the development of a dengue vaccine in
the 90’s. Clinical studies with the most advanced tetravalent candidate
vaccine started in the 2000’s. In a study in the United States, immunization
with three doses of Sanofi Pasteur’s tetravalent dengue vaccine candidate
generated a sero-neutralizing antibody response against all four serotypes of
the virus responsible for dengue fever in 100 percent of adults who
participated in the trial(1). The Sanofi Pasteur dengue vaccine research
program includes ongoing clinical studies in Mexico, Peru, and The
Philippines with adults and children.



About dengue fever



Dengue fever is a mosquito-borne disease caused by four types
of dengue viruses (type 1 to 4). Overall, the disease is a potential threat
for almost half the world’s population. Of the estimated 230 million people
infected annually, two million, mostly children, develop dengue hemorrhagic
fever (DHF), a severe form of the disease(2). DHF is a leading cause of
hospitalization in South-East Asia, placing tremendous pressure on strained
medical resources.



Dengue fever occurs mostly in tropical and subtropical
countries and is spreading to new parts of the globe each year. The WHO has
warned that the Western Pacific Region may be heading for a major dengue
outbreak(3). Outbreaks recently have been observed in Paraguay and the Middle
East. In addition, dengue affects countries such as Australia (Queensland)
and the United States (Puerto Rico, Texas-Mexico border, Hawaii and the
US-affiliated Pacific Islands). A substantial number of people traveling to
endemic regions are also infected each year.



About sanofi-aventis



Sanofi-aventis, a leading global pharmaceutical company,
discovers, develops and distributes therapeutic solutions to improve the
lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).



Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than 1.6 billion doses of vaccine in 2008, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, Sanofi Pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The company’s heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: http://www.sanofipasteur.com



References:



1. Data generated by the WHO Flavivirus Laboratory Reference Center,
Mahidol University, Bangkok, Thailand, presented at the American Society of
Tropical Medicine and Hygiene’s (ASTMH) 56th annual meeting held in
Philadelphia, Pennsylvania, USA



2. Pediatric Dengue Vaccine Initiative (PDVI), presentation “Estimating
the global burden of dengue” at 2nd Int Conf on Dengue & DHF, 15-17 Oct 08 ,
Phuket, Thailand



3. WHO alarmed about the spread of dengue,
http://www.wpro.who.int/media_centre/press_releases/pr_23072007.htm



Forward Looking Statements



This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include product development, product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the words
“expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and
similar expressions. Although sanofi-aventis’ management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the
FDA or the EMEA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could
affect the availability or commercial potential of such products candidates,
the absence of guarantee that the products candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives as well as those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for
the year ended December 31, 2007. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise any
forward-looking information or statements.



Sanofi Pasteur

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

Kaiser Family Foundation Webcast To Feature Live Q&A With Global Fund Executive Director Kazatchkine Gene Therapy Study Shows Method Is Safe, Somewhat Beneficial, Researchers Report

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,554 hits

%d bloggers like this: